AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval

Pharma To Carve HCC Niche On Survival Data

More than a decade after Pfizer gave up on it, tremelimumab won approval combined with PD-L1 inhibitor Imfinzi for frontline hepatocellular carcinoma, ahead of Bristol’s Yervoy/Opdivo second-line indication.

AstraZeneca announced the approval of Imjudo, combined with Imfinzi, in HCC • Source: Shutterstock

With its CTLA-4 inhibitor, Imjudo (tremelimumab), having finally won US Food and Drug Administration approval, AstraZeneca PLC is moving quickly to make it a competitor in the cancer immunotherapy space, where its most direct competitor, Bristol Myers Squibb Company’s Yervoy (ipilimumab), has long been well-established as a standard of care in multiple indications.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

30 Apr 2025

• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

28 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

25 Apr 2025

• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

Akeso Wins US Approval For PD-1 Antibody In NPC, Partly On US Data

25 Apr 2025

• By Dexter Jie Yan

Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.